Hemophilia A clinical trials
33 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
- Hemlibra in Mild Hemophilia A
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
- A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
- A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
- Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
- Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
- SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
- A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
- Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
- ASC618 Gene Therapy in Hemophilia A Patients
- A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
- Hemophilia A Research Program
- Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
- Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
- Treatment of Hemophilia A Patients With FVIII Inhibitors
- Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
- ATHNdataset Registry
- ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction
- TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies
- Liver Biopsy Following Gene Therapy For Hemophilia
- Study of a Smart Sharps Disposal Device in Patients With Hemophilia
- A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
- Early Check: Expanded Screening in Newborns
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Hemophilia A” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.